Literature DB >> 29066514

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells.

Fernando P Canale1, María C Ramello1, Nicolás Núñez2, Cintia L Araujo Furlan1, Sabrina N Bossio1, Melisa Gorosito Serrán1, Jimena Tosello Boari1, Andrés Del Castillo3, Marta Ledesma3, Christine Sedlik2,4, Eliane Piaggio2,4, Adriana Gruppi1, Eva A Acosta Rodríguez1, Carolina L Montes5.   

Abstract

The ability of CD8+ T lymphocytes to eliminate tumors is limited by their ability to engender an immunosuppressive microenvironment. Here we describe a subset of tumor-infiltrating CD8+ T cells marked by high expression of the immunosuppressive ATP ecto-nucleotidase CD39. The frequency of CD39highCD8+ T cells increased with tumor growth but was absent in lymphoid organs. Tumor-infiltrating CD8+ T cells with high CD39 expression exhibited features of exhaustion, such as reduced production of TNF and IL2 and expression of coinhibitory receptors. Exhausted CD39+CD8+ T cells from mice hydrolyzed extracellular ATP, confirming that CD39 is enzymatically active. Furthermore, exhausted CD39+CD8+ T cells inhibited IFNγ production by responder CD8+ T cells. In specimens from breast cancer and melanoma patients, CD39+CD8+ T cells were present within tumors and invaded or metastatic lymph nodes, but were barely detectable within noninvaded lymph nodes and absent in peripheral blood. These cells exhibited an exhausted phenotype with impaired production of IFNγ, TNF, IL2, and high expression of coinhibitory receptors. Although T-cell receptor engagement was sufficient to induce CD39 on human CD8+ T cells, exposure to IL6 and IL27 promoted CD39 expression on stimulated CD8+ T cells from human or murine sources. Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8+ T cells, with implications for defining a biomarker of T-cell dysfunction and a target for immunotherapeutic intervention.Significance: The tumor microenvironment elicits a subset of functionally exhausted CD8+ T cells by creating conditions that induce cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically targeted to restore effector T-cell function. Cancer Res; 78(1); 115-28. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29066514     DOI: 10.1158/0008-5472.CAN-16-2684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  112 in total

1.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

2.  Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent.

Authors:  Kristiyan Kanev; Ming Wu; Antar Drews; Patrick Roelli; Christine Wurmser; Madlaina von Hösslin; Dietmar Zehn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-17       Impact factor: 11.205

Review 3.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

4.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

5.  Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice.

Authors:  Sydney Lavoie; Eunyoung Chun; Sena Bae; Caitlin A Brennan; Carey Ann Gallini Comeau; Jessica K Lang; Monia Michaud; Hamid R Hoveyda; Graeme L Fraser; Miles H Fuller; Brian T Layden; Jonathan N Glickman; Wendy S Garrett
Journal:  Gastroenterology       Date:  2020-01-07       Impact factor: 22.682

6.  WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.

Authors:  Tatsuya Suwabe; Yasuhiko Shibasaki; Hiroyuki Sato; Suguru Tamura; Takayuki Katagiri; Hiroki Nemoto; Takuya Kasami; Takashi Kozakai; Ayako Nanba; Toshiki Kitajima; Kyoko Fuse; Takashi Ushiki; Hirohito Sone; Miwako Narita; Masayoshi Masuko
Journal:  Int J Hematol       Date:  2021-01-27       Impact factor: 2.490

7.  Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

Authors:  Shaun M O'Brien; Astero Klampatsa; Jeffrey C Thompson; Marina C Martinez; Wei-Ting Hwang; Abishek S Rao; Jason E Standalick; Soyeon Kim; Edward Cantu; Leslie A Litzky; Sunil Singhal; Evgeniy B Eruslanov; Edmund K Moon; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2019-05-03       Impact factor: 11.151

8.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

9.  TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers.

Authors:  Shuangqi Li; Jiuxing Feng; Feizhen Wu; Jiabin Cai; Xinyu Zhang; Haikun Wang; Irfete S Fetahu; Isabella Iwanicki; Dingailu Ma; Tao Hu; Hang Liu; Bingjie Wang; Guoming Shi; Li Tan; Yujiang Geno Shi
Journal:  EMBO Rep       Date:  2020-09-14       Impact factor: 8.807

Review 10.  Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

Authors:  Max M Wattenberg; Gregory L Beatty
Journal:  Semin Cancer Biol       Date:  2020-01-15       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.